Soho Global Health Tbk PT
IDX:SOHO

Watchlist Manager
Soho Global Health Tbk PT Logo
Soho Global Health Tbk PT
IDX:SOHO
Watchlist
Price: 670 IDR -0.74% Market Closed
Market Cap: 8.5T IDR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SOHO stock under the Base Case scenario is 730.52 IDR. Compared to the current market price of 670 IDR, Soho Global Health Tbk PT is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SOHO Relative Value
Base Case
730.52 IDR
Undervaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
72
vs Industry
73
Median 3Y
0.9
Median 5Y
0.9
Industry
2.5
More Details
18.1
P/E
P/E
Price to Earnings
18.1
vs History
50
vs Industry
27
Median 3Y
18.8
Median 5Y
18.3
Industry
21.3
More Details
25.3
P/OCF
P/OCF
Price to OCF
25.3
vs History
31
vs Industry
17
Median 3Y
25.2
Median 5Y
14.3
Industry
16.7
More Details
31.8
P/FCFE
P/FCFE
Price to FCFE
31.8
vs History
32
vs Industry
13
Median 3Y
31.8
Median 5Y
13.8
Industry
24.7
More Details
3
P/B
P/B
Price to Book Value
3
vs History
46
vs Industry
24
Median 3Y
3.1
Median 5Y
3
Industry
2.1
More Details
0.8
EV/S
EV/S
Enterprise Value to Sales
0.8
vs History
65
vs Industry
77
Median 3Y
0.8
Median 5Y
0.8
Industry
2.6
More Details
4.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.9
vs History
31
vs Industry
39
Median 3Y
4.9
Median 5Y
4.4
Industry
5.1
More Details
13.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.2
vs History
50
vs Industry
27
Median 3Y
13.6
Median 5Y
13.2
Industry
12.8
More Details
13.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.2
vs History
50
vs Industry
31
Median 3Y
13.6
Median 5Y
13.2
Industry
16.3
More Details
23.2
EV/OCF
EV/OCF
Enterprise Value to OCF
23.2
vs History
31
vs Industry
18
Median 3Y
22.9
Median 5Y
12.6
Industry
14.9
More Details
28.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
28.5
vs History
29
vs Industry
15
Median 3Y
28.2
Median 5Y
11.8
Industry
18.2
More Details
2.9
EV/IC
EV/IC
Enterprise Value to IC
2.9
vs History
56
vs Industry
26
Median 3Y
3.1
Median 5Y
3
Industry
1.9
More Details

Multiples Across Competitors

SOHO Competitors Multiples
Soho Global Health Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Soho Global Health Tbk PT
IDX:SOHO
8.5T IDR 0.8 18.1 13.2 13.2
US
Eli Lilly and Co
NYSE:LLY
699.1B USD 14.3 62.9 33.9 37
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.2 13.3 15.3
CH
Roche Holding AG
SIX:ROG
211.2B CHF 3.5 25.5 9.6 11.2
CH
Novartis AG
SIX:NOVN
184.2B CHF 4.2 17.4 10.3 13.8
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP 4.1 28.8 131 197.5
US
Merck & Co Inc
NYSE:MRK
193.3B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133.5B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
ID
Soho Global Health Tbk PT
IDX:SOHO
Average P/E: 24.1
18.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
62.9
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.5
32%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Soho Global Health Tbk PT
IDX:SOHO
Average EV/EBITDA: 395.2
13.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.9
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Soho Global Health Tbk PT
IDX:SOHO
Average EV/EBIT: 1 698.4
13.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.5
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

See Also

Summary
SOHO intrinsic value, competitors valuation, and company profile.
DCF Valuation
SOHO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SOHO stock valuation using valuation multiples.
Wall Street Estimates
SOHO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SOHO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.